New Survodutide Formulations Compared for Bioequivalence in Overweight Adults
Background
The peptide survodutide (BI 456906) is a promising dual GLP-1/glucagon receptor agonist currently under investigation for the treatment of obesity and overweight. As drug development progresses, optimizing the formulation is critical for consistent patient outcomes and manufacturing. This Phase 1 study addresses the specific knowledge gap of comparing the pharmacokinetic profiles of two different survodutide formulations to ensure they deliver the same amount of drug to the body.
Study Design
Results
This study is currently RECRUITING and has not yet reported findings, with an estimated completion date of 2027-03-02. However, its primary objective is to assess the bioequivalence of the two survodutide formulations. Researchers will measure key pharmacokinetic parameters, specifically the area under the concentration-time curve of survodutide in plasma at steady state over a uniform dosing interval (AUC tau,ss) and the maximum measured concentration of survodutide in plasma at steady state (Cmax,ss). These metrics will determine if Formulation A and Formulation B6 are absorbed and distributed similarly in the body. The ultimate goal is to demonstrate that both survodutide formulations deliver comparable total drug exposure and peak drug levels, ensuring consistent therapeutic effects.
Why It Matters
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not alter the drug's effectiveness or safety profile. Successful demonstration of bioequivalence in this trial could lead to the selection of an optimal survodutide formulation for future large-scale Phase 2 and Phase 3 clinical trials, potentially accelerating its path to becoming a widely available treatment for obesity.